Congress Puts Focus Back On Drug Pricing With AbbVie Subpoena

House Oversight Committee Chair says AbbVie has failed to comply with requests for documents in committee's investigation of the drug pricing of 12 pharma companies.

Congress and law as congressional subpoena and political legislation concept or government investigation and legislative reform in the United States with 3D illustration elements.
House ovesight committee plans to subpoena AbbVie for Humira and Imbruvica pricing information • Source: Shutterstock

Eighteen months after launching an investigation of the drug pricing practices of 12 companies, the House Committee on Oversight and Reform is singling out AbbVie Inc., claiming it has failed to turn over documents about the pricing of Humira (adalimumab) and Imbruvica (ibrutinib). The legal action brings the issue of drug pricing back to the forefront and could spur further policy debate as the presidential election campaign enters its final months.

Committee Chairwoman Carolyn Maloney, D-NY, announced on 1 September that she had sent a memo to committee members notifying them...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access